Evan A. Stein

31.0k total citations · 15 hit papers
224 papers, 22.6k citations indexed

About

Evan A. Stein is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Evan A. Stein has authored 224 papers receiving a total of 22.6k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Surgery, 74 papers in Endocrinology, Diabetes and Metabolism and 52 papers in Cancer Research. Recurrent topics in Evan A. Stein's work include Lipoproteins and Cardiovascular Health (182 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (64 papers) and Cancer, Lipids, and Metabolism (49 papers). Evan A. Stein is often cited by papers focused on Lipoproteins and Cardiovascular Health (182 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (64 papers) and Cancer, Lipids, and Metabolism (49 papers). Evan A. Stein collaborates with scholars based in United States, South Africa and Canada. Evan A. Stein's co-authors include Antonio M. Gotto, Frederick J. Raal, Deborah R. Shapiro, Michael Clearfield, Polly A. Beere, John R. Downs, Edwin J. Whitney, Alexandra Langendörfer, Stephen E. Weis and William B. Kruyer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Evan A. Stein

219 papers receiving 21.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

1998 4.1k citations Evan A. Stein et al. profile →
Estrogen plus Progestin and the Risk of Coronary Heart Disease

2003 1.4k citations Evan A. Stein et al. profile →
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

2003 1.1k citations Peter H. Jones, Evan A. Stein et al. The American Journal of Cardiology profile →
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. profile →
Implementation of the women's health initiative study design

2003 597 citations Evan A. Stein et al. profile →
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

2014 562 citations Frederick J. Raal, Evan A. Stein et al. The Lancet profile →
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

2014 553 citations Frederick J. Raal, Narimon Honarpour et al. The Lancet profile →
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

2012 505 citations Evan A. Stein, Scott Mellis et al. profile →
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

2012 463 citations Evan A. Stein, Daniel Gaudet et al. The Lancet profile →
THE RELATION OF DIET, CIGARETTE SMOKING, AND ALCOHOL CONSUMPTION TO PLASMA BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS

1988 456 citations Evan A. Stein et al. profile →
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

2012 416 citations James M. McKenney, Michael J. Koren et al. Journal of the American College of Cardiology profile →
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

2012 403 citations Frederick J. Raal, Robert C. Scott et al. Circulation profile →
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

2012 383 citations Eli M. Roth, James M. McKenney et al. profile →
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

2012 369 citations Robert C. Scott, Scott M. Wasserman et al. profile →
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology profile →

Peers

Countries citing papers authored by Evan A. Stein

Since Specialization

Citations

This map shows the geographic impact of Evan A. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan A. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan A. Stein more than expected).

Fields of papers citing papers by Evan A. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan A. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan A. Stein. The network helps show where Evan A. Stein may publish in the future.

Co-authorship network of co-authors of Evan A. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Evan A. Stein. A scholar is included among the top collaborators of Evan A. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan A. Stein. Evan A. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial 2025 ·The Lancet Diabetes & Endocrinology ·Frederick J. Raal, Vimal Mehta, Meral Kayıkçıoğlu, Dirk Blom, (unknown), Avishay Elis, Traci Turner, Christopher B. Daniels, Jeffrey Vest, Tracy Mitchell, (unknown), El Mustapha Bahassi, David Kallend, Evan A. Stein	6
2	Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD) 2024 ·Atherosclerosis ·(unknown), (unknown), (unknown), Lesley Burgess, Jane Kerr, (unknown), Jeffrey Vest, David Kallend, Evan A. Stein	2
3	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials 2022 ·Journal of clinical lipidology ·(unknown), Robert P. Giugliano, Marc S. Sabatine, Frederick J. Raal, Tamio Teramoto, Michael J. Koren, Evan A. Stein, Huei Wang, Maria Laura Monsalvo	6
4	Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study 2019 ·Circulation ·Evan A. Stein, Traci Turner, Dean J. Kereiakes, (unknown), (unknown), Rong Zhou	10
5	The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance 2015 ·American Journal of Respiratory and Critical Care Medicine ·Keith R. Walley, Gordon A. Francis, Steven M. Opal, Evan A. Stein, James A. Russell, John H. Boyd	45
6	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials) 2014 ·The American Journal of Cardiology ·Daniel Gaudet, Dean J. Kereiakes, James M. McKenney, Eli M. Roth, Corinne Hanotin, Daniel A. Gipe, Yunling Du, (unknown), Henry N. Ginsberg, Evan A. Stein	167
7	FRIEDEWALD FORMULA SIGNIFICANTLY UNDERESTIMATES LDL CHOLESTEROL COMPARED TO PREPARATIVE ULTRACENTRIFUGATION BELOW 70 MG/DL LEADING TO OVERESTIMATION OF THE LDL CHOLESTEROL REDUCTION FOR NEW DRUGS IN DEVELOPMENT 2014 ·Journal of the American College of Cardiology ·Evan A. Stein, Traci Turner, (unknown), Rong Zhou, (unknown)	5
8	LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY 2014 ·Journal of the American College of Cardiology ·Evan A. Stein, Sreeneeranj Kasichayanula, Traci Turner, (unknown), (unknown), (unknown), J. Jack Lee	44
9	EFFECT OF ROSUVASTATIN THERAPY ON ARTERIAL WALL CHANGES IN CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY 2014 ·Journal of the American College of Cardiology ·Gisle Langslet, Marjet J.A.M. Braamskamp, Brian W. McCrindle, David Cassiman, Gordon Francis, Claude Gagné, Daniel Gaudet, Katherine M. Morrison, Albert Wiegman, Traci Turner, Elinor Miller, Joel S. Raichlen, Paula Martin, Evan A. Stein, John J.P. Kastelein	2
10	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial breakdown → 2014 ·The Lancet ·Frederick J. Raal, Narimon Honarpour, Dirk Blom, G. Kees Hovingh, Feng Xu, Robert C. Scott, Scott M. Wasserman, Evan A. Stein	553
11	Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol 2012 ·Obstetrical & Gynecological Survey ·Evan A. Stein, Scott Mellis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William B. Smith, Eleanor Lisbon, María J. Gutiérrez, (unknown), Richard Wu, Yunling Du, (unknown), (unknown), Gary D. Swergold	10
12	Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443) 2012 ·Circulation ·Daniel Gaudet, Dean J. Kereiakes, (unknown), Eli M. Roth, Corinne Hanotin, (unknown), Yunling Du, (unknown), Henry N. Ginsberg, Evan A. Stein	2
13	Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia 2011 ·Circulation ·Gary D. Swergold, W. Smith, Scott Mellis, Douglas Logan, (unknown), Richard Wu, Yunling Du, (unknown), (unknown), Evan A. Stein	6
14	Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease 2009 ·Mayo Clinic Proceedings ·Evan A. Stein	1
15	Effects of Maximal Doses of Atorvastatin Versus Rosuvastatin on Small Dense Low-Density Lipoprotein Cholesterol Levels 2007 ·The American Journal of Cardiology ·Masumi Ai, Seiko Otokozawa, Bela F. Asztalos, Katsuyuki Nakajima, Evan A. Stein, Peter H. Jones, Ernst J. Schaefer	52
16	Pharmacotherapy for dyslipidaemia – current therapies and future agents 2003 ·Expert Opinion on Pharmacotherapy ·Harold Bays, Evan A. Stein	135
17	Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups 2003 ·The American Journal of Cardiology ·James W. Blasetto, Evan A. Stein, W. Virgil Brown, Rohini Chitra, Ali Raza	125
18	Association of lipoprotein(a), insulin resistance, and reproductive hormones in a multiethnic cohort of pre- and perimenopausal women (The SWAN Study) 2003 ·The American Journal of Cardiology ·MaryFran Sowers, Sybil L. Crawford, Jane A. Cauley, Evan A. Stein	25
19	Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor 1998 ·Journal of the American College of Cardiology ·Evan A. Stein, Jonathan L. Isaacsohn, Randall Stoltz, (unknown), (unknown), C. Lane, Allen H. Heller	7
20	The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: The pittsburgh epidemiology of diabetes complications study IX 1992 ·Metabolism ·June E. Eichner, R E Ferrell, M. Ilyas Kamboh, Lewis H. Kuller, Dorothy J. Becker, (unknown), Evan A. Stein, Trevor J. Orchard	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact